GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » Cyclically Adjusted Book per Share

Aptevo Therapeutics (Aptevo Therapeutics) Cyclically Adjusted Book per Share : $1,028.65 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Aptevo Therapeutics's adjusted book value per share data for the fiscal year that ended in Dec. 2023 was $27.621. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1,028.65 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Aptevo Therapeutics's average Cyclically Adjusted Book Growth Rate was -6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-04-30), Aptevo Therapeutics's current stock price is $ 0.7107. Aptevo Therapeutics's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec. 2023 was $1,028.65. Aptevo Therapeutics's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Aptevo Therapeutics was 0.10. The lowest was 0.01. And the median was 0.02.


Aptevo Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Aptevo Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptevo Therapeutics Cyclically Adjusted Book per Share Chart

Aptevo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1,102.91 1,028.65

Aptevo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,102.91 - - - 1,028.65

Competitive Comparison of Aptevo Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Aptevo Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptevo Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's Cyclically Adjusted PB Ratio falls into.



Aptevo Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aptevo Therapeutics's adjusted Book Value per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_Book=Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=27.621/129.4194*129.4194
=27.621

Current CPI (Dec. 2023) = 129.4194.

Aptevo Therapeutics Annual Data

Book Value per Share CPI Adj_Book
201412 2,956.500 99.070 3,862.215
201512 4.384 99.792 5.686
201612 1,536.493 101.863 1,952.157
201712 2,339.179 104.011 2,910.604
201812 821.118 105.998 1,002.554
201912 161.116 108.420 192.322
202012 165.526 109.897 194.931
202112 10.923 117.630 12.018
202212 122.305 125.222 126.405
202312 27.621 129.419 27.621

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Aptevo Therapeutics  (NAS:APVO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aptevo Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.7107/1028.65
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Aptevo Therapeutics was 0.10. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Aptevo Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptevo Therapeutics (Aptevo Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Executives
Daphne Taylor officer: SVP, CFO 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon officer: See Remarks APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux officer: Senior VP, Operations 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White director, officer: President and CEO 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi director 2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell officer: SVP, GC and Corporate Affairs 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman officer: SVP, Commercial Operations 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross officer: See Remarks 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121

Aptevo Therapeutics (Aptevo Therapeutics) Headlines